Naphthamides as Novel and Potent Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors: Design, Synthesis, and Evaluation

Jean-Christophe Harmange(Amgen (United States)), Roger Zanon(Amgen (United States)), Sesha Neervannan(Amgen (United States)), Matthew M. Weiss(Amgen (United States)), Michael Schrag(Amgen (United States)), Danlin Chen(Amgen (United States)), Julie Flynn(Amgen (United States)), Ryan D. White(Amgen (United States)), Juan Estrada(Amgen (United States)), Douglas A. Whittington(Amgen (United States)), George Borg(Aalborg University), Andrew S. Tasker(Amgen (United States)), Julie Germain(Amgen (United States)), Anthony Polverino(Amgen (United States)), Deborah M. Choquette(Amgen (United States)), Tom DeMelfi(Amgen (United States)), Charlie Starnes(Amgen (United States)), Michele Potashman(Biogen (United States)), Russell F. Graceffa(Amgen (United States)), Phillip M. Roveto(Amgen (United States)), Matthew W. Martin(Amgen (United States)), Shawn Harriman(Amgen (United States)), James Bready(Amgen (United States)), Alexander Long(Amgen (United States)), Vinod F. Patel(Guy's Hospital), Daniel S. La(Amgen (United States)), Nicholas Doerr(Amgen (United States)), Kelly Regal(Amgen (United States)), Yohannes Teffera(Amgen (United States)), Ling Wang(Mayo Clinic), Angela Coxon(Amgen (United States)), Stephen A. Kaufman(Amgen (United States)), Lucian DiPietro(Blueprint Medicines (United States))
Journal of Medicinal Chemistry
March 1, 2008
Cited by 70


Related Papers